Načítá se...
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
BACKGROUND: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the seco...
Uloženo v:
| Vydáno v: | Int J Nephrol Renovasc Dis |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822864/ https://ncbi.nlm.nih.gov/pubmed/27099525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S83874 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|